These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20166188)

  • 1. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):575-82. PubMed ID: 20166188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
    Intervirology; 2012; 55(6):417-25. PubMed ID: 21325786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.
    Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Fukuda K; Mita E; Haruna Y; Inoue A; Imai Y; Hosui A; Miyagi T; Yoshida Y; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Med Virol; 2011 Mar; 83(3):419-27. PubMed ID: 21264862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
    Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2009 Mar; 81(3):452-8. PubMed ID: 19152407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    Intervirology; 2007; 50(5):361-8. PubMed ID: 17728547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2013 Jun; 85(6):1028-36. PubMed ID: 23588728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1354-62. PubMed ID: 18551609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
    Miyasaka A; Kumagai I; Abe K; Suzuki K
    Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
    Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
    Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K
    J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J;
    J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
    Yang CC; Tsai WL; Su WW; Huang CF; Cheng PN; Lo CC; Tseng KC; Mo LR; Wang CH; Hsu SJ; Lai HC; Su CW; Liu CJ; Peng CY; Yu ML
    PLoS One; 2015; 10(9):e0137852. PubMed ID: 26368130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.